Compugen

This week, Compugen provided details about an informatics platform it is developing internally for identifying protein functional interaction sites as part of its efforts to discover functional monoclonal antibodies in oncology and immunology that can be used as therapeutic candi

NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Compugen and DiscoveRx today announced a collaboration to commercialize specially designed peptides matched with specific G protein-coupled receptor targets.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its third quarter, the same as in the year-ago period.

The company saw a 146 percent increase year over year in its net loss to $2.2 million.

The firm cut its loss on lower marketing and business development costs.

While it didn't need necessarily need the money from the IPO to continue operations, the money raised will allow Rosetta Green to “ramp up more quickly and accelerate the work they are doing,” a Rosetta Genomics official said.

The company's revenues rose sharply for both the quarter and year, but Compugen cautioned that its revenues are subject to substantial fluctuations.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.